HC Wainwright Reaffirms “Buy” Rating for Genmab A/S (NASDAQ:GMAB)

Genmab A/S (NASDAQ:GMAB)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $50.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 125.33% from the company’s current price.

A number of other brokerages also recently commented on GMAB. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Morgan Stanley restated an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a report on Wednesday, September 11th. Redburn Atlantic assumed coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They set a “buy” rating on the stock. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $48.00 target price (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Stock Up 0.0 %

Shares of NASDAQ:GMAB opened at $22.19 on Wednesday. The company has a market capitalization of $14.68 billion, a P/E ratio of 21.54, a P/E/G ratio of 0.63 and a beta of 0.97. Genmab A/S has a 52-week low of $19.85 and a 52-week high of $32.56. The stock’s fifty day simple moving average is $21.32 and its 200-day simple moving average is $24.25.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The firm had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. During the same quarter last year, the firm earned $0.47 earnings per share. On average, sell-side analysts anticipate that Genmab A/S will post 1.28 earnings per share for the current year.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently bought and sold shares of the business. Legacy Wealth Asset Management LLC grew its stake in Genmab A/S by 1.1% during the third quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company’s stock worth $1,097,000 after buying an additional 471 shares during the period. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Genmab A/S by 7.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after acquiring an additional 478 shares in the last quarter. GAMMA Investing LLC boosted its position in Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after purchasing an additional 1,051 shares during the period. Eagle Asset Management Inc. boosted its position in Genmab A/S by 10.0% during the 3rd quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock worth $285,000 after purchasing an additional 1,121 shares during the period. Finally, Rhumbline Advisers increased its holdings in Genmab A/S by 7.1% in the 2nd quarter. Rhumbline Advisers now owns 18,694 shares of the company’s stock valued at $470,000 after purchasing an additional 1,236 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.